Optimizing Heart Failure Treatment: A Review of the 2024 ACC Expert Consensus Decision Pathway

Abstract

Heart failure with reduced ejection fraction (HFrEF) is a debilitating condition. Fortunately, significant advancements have been made in treatment strategies. This review explores the 2024 American College of Cardiology (ACC) Expert Consensus Decision Pathway for HFrEF, a valuable resource for optimizing patient care. We delve into the core components of guideline-directed medical therapy (GDMT), highlighting the latest recommendations on medications like angiotensin receptor neprilysin inhibitors (ARNIs), SGLT2 inhibitors, and beta-blockers. Additionally, we discuss the importance of early treatment initiation and potential considerations for advanced therapies like vericiguat.

Introduction

Millions worldwide struggle with heart failure, a condition where the heart weakens and struggles to pump blood effectively. Heart failure with reduced ejection fraction (HFrEF), characterized by a weakened left ventricle, presents a significant burden. However, hope exists. The 2024 ACC Expert Consensus Decision Pathway for HFrEF offers a roadmap for clinicians to optimize treatment strategies and improve patient outcomes.

Guideline-Directed Medical Therapy (GDMT): The Core of HFrEF Treatment

The cornerstone of HFrEF management remains GDMT, a multi-drug approach that targets various aspects of the disease process.

• Angiotensin receptor neprilysin inhibitors (ARNIs): These medications have emerged as the preferred first-line therapy due to their superior efficacy in reducing hospitalizations and mortality compared to angiotensin-converting enzyme (ACE) inhibitors.

• Sodium-glucose cotransporter-2 (SGLT2) Inhibitors: These drugs hold promise not only for managing diabetes but also for improving cardiovascular outcomes in patients with HFrEF, including reducing hospitalizations.

• Beta-blockers: Beta-blockers remain essential for HFrEF, but careful patient selection and gradual dose titration are crucial to manage potential side effects.

• Other GDMT Components: Diuretics, mineralocorticoid antagonists (MRAs), and ivabradine are also included in the treatment regimen, each playing a specific role in managing fluid balance and heart function.

Early Intervention and Tailored Approaches

The 2024 ACC Decision Pathway emphasizes the importance of initiating GDMT as early as possible after diagnosis, ideally within 3 months. This early intervention can significantly improve outcomes. Additionally, the pathway acknowledges the need for individualized treatment plans, considering factors like patient comorbidities and medication tolerance.

Advanced Therapies: Expanding the Treatment Horizon

The review explores the potential role of emerging therapies like vericiguat, a drug that has shown promise in reducing hospitalizations and cardiovascular death in high-risk HFrEF patients already on GDMT.

Conclusion

The 2024 ACC Expert Consensus Decision Pathway provides a valuable framework for optimizing HFrEF treatment. By implementing evidence-based GDMT with early initiation, individualized approaches, and consideration of emerging therapies, clinicians can equip themselves to improve the lives of patients with HFrEF.